Literature DB >> 16595368

Modulation of human immunodeficiency virus infection by anticonvulsant drugs.

Barry Robinson1, Jadwiga Turchan, Caroline Anderson, Ashok Chauhan, Avindra Nath.   

Abstract

Patients with human immunodeficiency virus (HIV) infection often require treatment with anticonvulsants either for treatment of seizures or occasionally for pain control. In this study, the authors determined if the anticonvulsants phenytoin, carbamazepine, and valproate could modulate HIV replication. These drugs activated HIV replication in latently infected monocytic cells but not in latently infected lymphocytic cells at clinically relevant dosages. The activation in the monocytic cells was as a result of transactivation of HIV long terminal repeat (LTR) and could be seen at therapeutic dosages whereas no effect was seen on LTR activation in lymphocytic cells. When the drugs were used in conjunction with known transactivators of HIV LTR such as Tat and phorbol-12-myristate-13-acetate (PMA), no additive or synergistic effect was noted. Although the clinical relevance of these observations needs to be determined, these observations may suggest that monitoring of cerebrospinal fluid (CSF) viral load maybe needed in HIV-infected patients treated with anticonvulsants, because HIV-infected macrophages are important in mediating HIV dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16595368     DOI: 10.1080/13550280500516278

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  15 in total

1.  Protease inhibitor-induced carbamazepine toxicity.

Authors:  A Berbel Garcia; A Latorre Ibarra; J Porta Etessam; A Martinez Salio; D Perez Martinez; R Siaz Diaz; M Toledo Heras
Journal:  Clin Neuropharmacol       Date:  2000 Jul-Aug       Impact factor: 1.592

2.  Primary headaches in HIV-infected patients.

Authors:  S M Mirsattari; C Power; A Nath
Journal:  Headache       Date:  1999-01       Impact factor: 5.887

3.  Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

Authors:  P W Hugen; D M Burger; K Brinkman; H J ter Hofstede; R Schuurman; P P Koopmans; Y A Hekster
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

Review 4.  Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia.

Authors:  Avi Nath
Journal:  J Infect Dis       Date:  2002-12-01       Impact factor: 5.226

5.  Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro.

Authors:  M Witvrouw; J C Schmit; B Van Remoortel; D Daelemans; J A Esté; A M Vandamme; J Desmyter; E De Clercq
Journal:  AIDS Res Hum Retroviruses       Date:  1997-01-20       Impact factor: 2.205

6.  Painful Peripheral Neuropathy.

Authors:  Gil I. Wolfe; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.598

7.  Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels.

Authors:  C Moog; G Kuntz-Simon; C Caussin-Schwemling; G Obert
Journal:  J Gen Virol       Date:  1996-09       Impact factor: 3.891

8.  Seizures in human immunodeficiency virus infection.

Authors:  M C Wong; N D Suite; D R Labar
Journal:  Arch Neurol       Date:  1990-06

9.  Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders.

Authors:  Scott L Letendre; J Allen McCutchan; Meredith E Childers; Steven P Woods; Deborah Lazzaretto; Robert K Heaton; Igor Grant; Ronald J Ellis
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

10.  An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation.

Authors:  V L Perez; T Rowe; J S Justement; S T Butera; C H June; T M Folks
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

View more
  4 in total

Review 1.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.

Authors:  Jeffrey A Rumbaugh; Joseph Steiner; Ned Sacktor; Avindra Nath
Journal:  Futur HIV Ther       Date:  2008

3.  Valproic acid does not affect markers of human immunodeficiency virus disease progression.

Authors:  Beau M Ances; Scott Letendre; Maria Buzzell; Jennifer Marquie-Beck; Deborah Lazaretto; Thomas D Marcotte; Igor Grant; Ronald J Ellis
Journal:  J Neurovirol       Date:  2006-10       Impact factor: 2.643

4.  Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS.

Authors:  Kathy Lee; Pornpun Vivithanaporn; Reed A Siemieniuk; Hartmut B Krentz; Ferdinand Maingat; M John Gill; Christopher Power
Journal:  BMC Neurol       Date:  2010-06-17       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.